Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. Company
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Number of employees : 24 300 people.
Sales per Business
20192020Delta
Human Therapeutics22 204.0095.5%24 240.0096% +9.17%
Other1 158.005%1 184.004.7% +2.25%
USD in Million
Sales per region
20192020Delta
United States17 224.0074%18 496.0073.3% +7.39%
Rest of the World5 962.0025.6%6 787.0026.9% +13.84%
Canada176.000.8%141.000.6% -19.89%
USD in Million
Managers
Name Title Age Since
Robert Bradway Chairman, President & Chief Executive Officer 57 -
Peter Griffith Chief Financial Officer & Executive Vice President 61 2020
David Reese Executive Vice President-Research & Development 57 2018
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical - 2018
Mike Zahigian Chief Information Officer & Senior Vice President - 2017
Saptarsi Haldar VP-Research & Head-Cardiometabolic Disorders - -
Esteban Santos Executive Vice President-Operations 52 2016
Nancy Grygiel Chief Compliance Officer 52 2020
Ronald Sugar Independent Director 72 2011
Tyler E. Jacks, Dr. Independent Director 59 2012
Members of the board
Name Title Age Since
Robert Bradway Chairman, President & Chief Executive Officer 57 -
Ronald Sugar Independent Director 72 2011
Tyler E. Jacks, Dr. Independent Director 59 2012
Robert Eckert Lead Independent Director 65 2012
Greg Garland Independent Director 62 2013
Robert Sanders Williams, Dr. Independent Director 71 2014
Ellen Kullman Independent Director 64 2016
Charles M. Holley Independent Director 63 2017
Wanda M. Austin, Dr. Independent Director 65 2017
Brian J. Druker, Dr. Independent Director 64 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 563,265,902 562,062,880 99.8% 0 0.0% 99.8%
Shareholders
NameEquities%
Capital Research & Management Co. 71,504,200 12.6%
The Vanguard Group, Inc. 44,336,367 7.81%
SSgA Funds Management, Inc. 29,641,701 5.22%
Capital Research & Management Co. (Global Investors) 26,724,181 4.71%
PRIMECAP Management Co. 16,082,687 2.83%
BlackRock Fund Advisors 12,466,871 2.20%
NWQ Investment Management Co. LLC 11,762,842 2.07%
Geode Capital Management LLC 10,362,110 1.82%
Morgan Stanley Smith Barney LLC (Investment Management) 8,388,102 1.48%
Sands Capital Management LLC 8,360,926 1.47%
Holdings
NameEquities%Valuation
BEIGENE, LTD. (6160) 246,269,426 20.3% 6,895,120,345 USD
AKERO THERAPEUTICS, INC. (AKRO) 1,508,375 4.32% 32,414,979 USD
IMAGO BIOSCIENCES, INC. (IMGO) 1,193,047 3.57% 31,758,911 USD
JASPER THERAPEUTICS, INC. (JSPR) 2,700,000 7.39% 24,651,000 USD
PROVENTION BIO, INC. (PRVB) 2,500,000 3.94% 15,650,000 USD
BEIGENE, LTD. 246,269,426 20.2% 2,463 USD
Markets and indexes
- International Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Company contact information
Amgen Inc.
1 Amgen Center Drive
CA 91320-1799 Thousand Oaks, California

Phone : +1 805 447 1000
Fax : +1 805 447 1010
web site : https://investors.amgen.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Amgen Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
AMGEN INC.-11.95%114 028
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641
ABBVIE INC.8.18%210 113
MERCK & CO., INC.-10.34%185 253
NOVARTIS AG-12.05%179 058
ASTRAZENECA PLC11.84%167 779
BRISTOL-MYERS SQUIBB COMPANY-9.21%125 010
SANOFI6.44%118 698
GLAXOSMITHKLINE PLC14.35%101 616
CHUGAI PHARMACEUTICAL CO., LTD.-33.20%53 454
JIANGSU HENGRUI MEDICINE CO., LTD.-47.03%49 171
BAYER AG-8.10%49 077
DAIICHI SANKYO COMPANY, LIMITED-19.48%48 251
TAKEDA PHARMACEUTICAL COMPANY LIMITED-18.24%42 287
ASTELLAS PHARMA INC.11.79%29 201
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY36.49%22 646
CATALENT, INC.17.68%20 965